Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Matson Inc (MATX) vs Twist Bioscience Corp (TWST) Price & Performance

Matson IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Matson Inc vs Twist Bioscience Corp — how do they compare? Matson Inc trades at $212.65 (market cap $6.11B), while Twist Bioscience Corp trades at $123.1 (market cap $7.72B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Matson Inc pays a 0.74% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

MATXTWST
Market Cap
$6.11B$7.72B
Sector
TechnologyHealth
52-Week High
$223.55$124.88
52-Week Low
$88.05$24.16
Enterprise Value
$6.71B$7.65B
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Matson Inc

Matson (MATX) trades at $212.05, up 1.61% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.27 surpassing expectations. Revenue and net income are trending upward, supported by a robust China service and resilient consumer demand. The company's valuation ratios, including a P/E of 13.79 and EV/EBITDA of 7.78, appear reasonable relative to earnings growth.

The outlook for MATX is positive, driven by earnings momentum and a favorable analyst consensus with a $265 price target implying significant upside. Key opportunities include continued trade flow strength and dividend growth, while risks involve Trans-Pacific trade volatility and broader economic pressures. The stock presents a compelling case for growth-oriented investors seeking exposure to niche shipping services.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

About Matson Inc

Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.

Read more on MATX

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST